The PI3K/AKT Pathway and Renal Cell Carcinoma

Huifang Guo, Peter German, Shanshan Bai, Sean Barnes, Wei Guo, Xiangjie Qi, Hongxiang Lou, Jiyong Liang, Eric Jonasch, Gordon Mills, Zhiyong Ding

Research output: Contribution to journalReview article

78 Citations (Scopus)

Abstract

The phosphatidylinositol 3 kinase (PI3K)/AKT pathway is genetically targeted in more pathway components and in more tumor types than any other growth factor signaling pathway, and thus is frequently activated as a cancer driver. More importantly, the PI3K/AKT pathway is composed of multiple bifurcating and converging kinase cascades, providing many potential targets for cancer therapy. Renal cell carcinoma (RCC) is a high-risk and high-mortality cancer that is notoriously resistant to traditional chemotherapies or radiotherapies. The PI3K/AKT pathway is modestly mutated but highly activated in RCC, representing a promising drug target. Indeed, PI3K pathway inhibitors of the rapalog family are approved for use in RCC. Recent large-scale integrated analyses of a large number of patients have provided a molecular basis for RCC, reiterating the critical role of the PI3K/AKT pathway in this cancer. In this review, we summarize the genetic alterations of the PI3K/AKT pathway in RCC as indicated in the latest large-scale genome sequencing data, as well as treatments for RCC that target the aberrant activated PI3K/AKT pathway.

Original languageEnglish (US)
Pages (from-to)343-353
Number of pages11
JournalJournal of Genetics and Genomics
Volume42
Issue number7
DOIs
StatePublished - Jul 20 2015
Externally publishedYes

Fingerprint

Phosphatidylinositol 3-Kinase
Renal Cell Carcinoma
Neoplasms
Intercellular Signaling Peptides and Proteins
Phosphotransferases
Radiotherapy
Genome
Drug Therapy
Mortality
Therapeutics

Keywords

  • AKT
  • MTOR
  • PI3K
  • Renal cell carcinoma
  • Targeted therapy

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics

Cite this

Guo, H., German, P., Bai, S., Barnes, S., Guo, W., Qi, X., ... Ding, Z. (2015). The PI3K/AKT Pathway and Renal Cell Carcinoma. Journal of Genetics and Genomics, 42(7), 343-353. https://doi.org/10.1016/j.jgg.2015.03.003

The PI3K/AKT Pathway and Renal Cell Carcinoma. / Guo, Huifang; German, Peter; Bai, Shanshan; Barnes, Sean; Guo, Wei; Qi, Xiangjie; Lou, Hongxiang; Liang, Jiyong; Jonasch, Eric; Mills, Gordon; Ding, Zhiyong.

In: Journal of Genetics and Genomics, Vol. 42, No. 7, 20.07.2015, p. 343-353.

Research output: Contribution to journalReview article

Guo, H, German, P, Bai, S, Barnes, S, Guo, W, Qi, X, Lou, H, Liang, J, Jonasch, E, Mills, G & Ding, Z 2015, 'The PI3K/AKT Pathway and Renal Cell Carcinoma', Journal of Genetics and Genomics, vol. 42, no. 7, pp. 343-353. https://doi.org/10.1016/j.jgg.2015.03.003
Guo H, German P, Bai S, Barnes S, Guo W, Qi X et al. The PI3K/AKT Pathway and Renal Cell Carcinoma. Journal of Genetics and Genomics. 2015 Jul 20;42(7):343-353. https://doi.org/10.1016/j.jgg.2015.03.003
Guo, Huifang ; German, Peter ; Bai, Shanshan ; Barnes, Sean ; Guo, Wei ; Qi, Xiangjie ; Lou, Hongxiang ; Liang, Jiyong ; Jonasch, Eric ; Mills, Gordon ; Ding, Zhiyong. / The PI3K/AKT Pathway and Renal Cell Carcinoma. In: Journal of Genetics and Genomics. 2015 ; Vol. 42, No. 7. pp. 343-353.
@article{d52768427d2f430dbeee0e57eafc8868,
title = "The PI3K/AKT Pathway and Renal Cell Carcinoma",
abstract = "The phosphatidylinositol 3 kinase (PI3K)/AKT pathway is genetically targeted in more pathway components and in more tumor types than any other growth factor signaling pathway, and thus is frequently activated as a cancer driver. More importantly, the PI3K/AKT pathway is composed of multiple bifurcating and converging kinase cascades, providing many potential targets for cancer therapy. Renal cell carcinoma (RCC) is a high-risk and high-mortality cancer that is notoriously resistant to traditional chemotherapies or radiotherapies. The PI3K/AKT pathway is modestly mutated but highly activated in RCC, representing a promising drug target. Indeed, PI3K pathway inhibitors of the rapalog family are approved for use in RCC. Recent large-scale integrated analyses of a large number of patients have provided a molecular basis for RCC, reiterating the critical role of the PI3K/AKT pathway in this cancer. In this review, we summarize the genetic alterations of the PI3K/AKT pathway in RCC as indicated in the latest large-scale genome sequencing data, as well as treatments for RCC that target the aberrant activated PI3K/AKT pathway.",
keywords = "AKT, MTOR, PI3K, Renal cell carcinoma, Targeted therapy",
author = "Huifang Guo and Peter German and Shanshan Bai and Sean Barnes and Wei Guo and Xiangjie Qi and Hongxiang Lou and Jiyong Liang and Eric Jonasch and Gordon Mills and Zhiyong Ding",
year = "2015",
month = "7",
day = "20",
doi = "10.1016/j.jgg.2015.03.003",
language = "English (US)",
volume = "42",
pages = "343--353",
journal = "Journal of Genetics and Genomics",
issn = "1673-8527",
publisher = "Institute of Genetics and Developmental Biology",
number = "7",

}

TY - JOUR

T1 - The PI3K/AKT Pathway and Renal Cell Carcinoma

AU - Guo, Huifang

AU - German, Peter

AU - Bai, Shanshan

AU - Barnes, Sean

AU - Guo, Wei

AU - Qi, Xiangjie

AU - Lou, Hongxiang

AU - Liang, Jiyong

AU - Jonasch, Eric

AU - Mills, Gordon

AU - Ding, Zhiyong

PY - 2015/7/20

Y1 - 2015/7/20

N2 - The phosphatidylinositol 3 kinase (PI3K)/AKT pathway is genetically targeted in more pathway components and in more tumor types than any other growth factor signaling pathway, and thus is frequently activated as a cancer driver. More importantly, the PI3K/AKT pathway is composed of multiple bifurcating and converging kinase cascades, providing many potential targets for cancer therapy. Renal cell carcinoma (RCC) is a high-risk and high-mortality cancer that is notoriously resistant to traditional chemotherapies or radiotherapies. The PI3K/AKT pathway is modestly mutated but highly activated in RCC, representing a promising drug target. Indeed, PI3K pathway inhibitors of the rapalog family are approved for use in RCC. Recent large-scale integrated analyses of a large number of patients have provided a molecular basis for RCC, reiterating the critical role of the PI3K/AKT pathway in this cancer. In this review, we summarize the genetic alterations of the PI3K/AKT pathway in RCC as indicated in the latest large-scale genome sequencing data, as well as treatments for RCC that target the aberrant activated PI3K/AKT pathway.

AB - The phosphatidylinositol 3 kinase (PI3K)/AKT pathway is genetically targeted in more pathway components and in more tumor types than any other growth factor signaling pathway, and thus is frequently activated as a cancer driver. More importantly, the PI3K/AKT pathway is composed of multiple bifurcating and converging kinase cascades, providing many potential targets for cancer therapy. Renal cell carcinoma (RCC) is a high-risk and high-mortality cancer that is notoriously resistant to traditional chemotherapies or radiotherapies. The PI3K/AKT pathway is modestly mutated but highly activated in RCC, representing a promising drug target. Indeed, PI3K pathway inhibitors of the rapalog family are approved for use in RCC. Recent large-scale integrated analyses of a large number of patients have provided a molecular basis for RCC, reiterating the critical role of the PI3K/AKT pathway in this cancer. In this review, we summarize the genetic alterations of the PI3K/AKT pathway in RCC as indicated in the latest large-scale genome sequencing data, as well as treatments for RCC that target the aberrant activated PI3K/AKT pathway.

KW - AKT

KW - MTOR

KW - PI3K

KW - Renal cell carcinoma

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=84938288040&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938288040&partnerID=8YFLogxK

U2 - 10.1016/j.jgg.2015.03.003

DO - 10.1016/j.jgg.2015.03.003

M3 - Review article

VL - 42

SP - 343

EP - 353

JO - Journal of Genetics and Genomics

JF - Journal of Genetics and Genomics

SN - 1673-8527

IS - 7

ER -